JP4384918B2 - ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 - Google Patents
ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 Download PDFInfo
- Publication number
- JP4384918B2 JP4384918B2 JP2003585719A JP2003585719A JP4384918B2 JP 4384918 B2 JP4384918 B2 JP 4384918B2 JP 2003585719 A JP2003585719 A JP 2003585719A JP 2003585719 A JP2003585719 A JP 2003585719A JP 4384918 B2 JP4384918 B2 JP 4384918B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- mmol
- alkoxy
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- MYWRFWIOHPWSRV-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2NC(CC(F)(F)F)CNc(cccc2)c2N)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2NC(CC(F)(F)F)CNc(cccc2)c2N)=O)ccn1)=O MYWRFWIOHPWSRV-UHFFFAOYSA-N 0.000 description 1
- NRYHYGHRURUTGW-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2c([nH]c2c3)nc2ccc3Cl)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(N(CC2)CCC2c([nH]c2c3)nc2ccc3Cl)=O)ccn1)=O NRYHYGHRURUTGW-UHFFFAOYSA-N 0.000 description 1
- FLHKAPFHVVDFBD-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(O)=O)ccn1)=O Chemical compound CC(C)(C)OC(Nc1cc(CN(CC2)CCC2C(O)=O)ccn1)=O FLHKAPFHVVDFBD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373102P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011672 WO2003088967A1 (en) | 2002-04-18 | 2003-04-16 | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005529116A JP2005529116A (ja) | 2005-09-29 |
| JP2005529116A5 JP2005529116A5 (https=) | 2006-12-21 |
| JP4384918B2 true JP4384918B2 (ja) | 2009-12-16 |
Family
ID=29251069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003585719A Expired - Lifetime JP4384918B2 (ja) | 2002-04-18 | 2003-04-16 | ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1499316B1 (https=) |
| JP (1) | JP4384918B2 (https=) |
| KR (1) | KR100827470B1 (https=) |
| CN (1) | CN100522166C (https=) |
| AR (1) | AR040405A1 (https=) |
| AT (1) | ATE389406T1 (https=) |
| AU (1) | AU2003223627B2 (https=) |
| BR (1) | BR0309348A (https=) |
| CA (1) | CA2481940A1 (https=) |
| CY (1) | CY1110363T1 (https=) |
| DE (1) | DE60319813T2 (https=) |
| DK (1) | DK1499316T3 (https=) |
| EC (1) | ECSP045367A (https=) |
| ES (1) | ES2301791T3 (https=) |
| IL (1) | IL164584A (https=) |
| MX (1) | MXPA04010173A (https=) |
| NO (1) | NO20045002L (https=) |
| NZ (1) | NZ535763A (https=) |
| PE (1) | PE20040684A1 (https=) |
| PL (1) | PL373889A1 (https=) |
| PT (1) | PT1499316E (https=) |
| RU (1) | RU2323935C2 (https=) |
| SI (1) | SI1499316T1 (https=) |
| TW (1) | TW200306183A (https=) |
| WO (1) | WO2003088967A1 (https=) |
| ZA (1) | ZA200407984B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE552236T1 (de) | 2003-01-14 | 2012-04-15 | Cytokinetics Inc | Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz |
| CA2523431A1 (en) | 2003-04-23 | 2004-11-25 | Glaxo Group Limited | Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases |
| ES2522579T3 (es) | 2004-06-17 | 2014-11-17 | Cytokinetics, Inc. | Compuestos, composiciones y métodos |
| US7176222B2 (en) | 2004-07-27 | 2007-02-13 | Cytokinetics, Inc. | Syntheses of ureas |
| US20080021069A1 (en) * | 2004-10-08 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Receptor Function Regulating Agent |
| EP1848696A1 (en) * | 2005-01-21 | 2007-10-31 | Schering Corporation | Imidazole and benzimidazole derivates useful as histamine h3 antagonists |
| TW200738676A (en) * | 2005-06-20 | 2007-10-16 | Schering Corp | Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| ATE450525T1 (de) * | 2005-06-20 | 2009-12-15 | Schering Corp | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007035703A1 (en) * | 2005-09-20 | 2007-03-29 | Schering Corporation | 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4 , 5-b] pyridin-3-yl] piperidine useful as histamine h3 antagonist |
| ATE429428T1 (de) | 2005-09-30 | 2009-05-15 | Hoffmann La Roche | Indanderivate als antagonisten des mch-rezeptors |
| ES2419007T3 (es) | 2005-12-15 | 2013-08-19 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y procedimientos |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7638531B2 (en) | 2005-12-21 | 2009-12-29 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists |
| EP1965862A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| RU2008132966A (ru) * | 2006-01-13 | 2010-02-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Производные циклогексилпиперазинилметанона и их применение в качестве модуляторов гистамин н3 рецептора |
| TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| CN101809021B (zh) * | 2007-09-11 | 2013-04-24 | 雅培制药有限公司 | 八氢-吡咯并[3,4-b]吡咯n-氧化物 |
| GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
| CA2785536C (en) | 2009-12-30 | 2018-02-27 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| WO2012177852A1 (en) | 2011-06-24 | 2012-12-27 | Arqule, Inc | Substituted imidazopyridinyl compounds |
| US8609688B2 (en) | 2011-06-24 | 2013-12-17 | Arqule, Inc. | Substituted imidazopyridinyl-aminopyridine compounds |
| KR101127756B1 (ko) | 2011-09-02 | 2012-03-23 | 한국과학기술원 | Ｇｉｔ１ 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법 |
| WO2013151982A1 (en) | 2012-04-03 | 2013-10-10 | Arena Pharmaceuticals, Inc. | Methods and compounds useful in treating pruritus, and methods for identifying such compounds |
| JP6046646B2 (ja) * | 2014-01-10 | 2016-12-21 | 信越化学工業株式会社 | オニウム塩、化学増幅型ポジ型レジスト組成物、及びパターン形成方法 |
| US10595550B2 (en) * | 2014-01-22 | 2020-03-24 | Vision Pharma, Llc | Therapeutic composition including carbonated solution |
| WO2017035114A1 (en) * | 2015-08-25 | 2017-03-02 | Janssen Pharmaceutica Nv | Benzimidazole derivatives useful as cb-1 inverse agonists |
| MA55556A (fr) | 2019-04-02 | 2022-02-09 | Aligos Therapeutics Inc | Composés ciblant prmt5 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD290192A5 (de) * | 1986-11-13 | 1991-05-23 | Eisai Co. Ltd,Jp | Pyridinderivat mit antiulzeroeser wirkung |
| ES2048109B1 (es) * | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| DE69415391T2 (de) * | 1993-05-26 | 1999-08-26 | Sumitomo Pharmaceuticals Co. | Chinazolinonderivate |
| US6211199B1 (en) * | 1995-11-17 | 2001-04-03 | Aventis Pharmaceuticals Inc. | Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases |
| CA2247105C (en) * | 1996-02-21 | 2002-05-14 | Hoechst Marion Roussel, Inc. | Novel substituted n-methyl-n-(4-(4-(1h-benzimidazol-2-yl-amino)piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic di seases |
| EP0980359B1 (en) * | 1997-05-01 | 2004-06-23 | Nissan Chemical Industries, Ltd. | Benzimidazole derivative |
| US6133291A (en) * | 1998-10-16 | 2000-10-17 | Schering Corporation | N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists |
| AU2001292730A1 (en) * | 2000-09-20 | 2002-04-02 | Schering Corporation | Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| US7220735B2 (en) * | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
-
2003
- 2003-04-16 NZ NZ535763A patent/NZ535763A/en not_active IP Right Cessation
- 2003-04-16 BR BR0309348-4A patent/BR0309348A/pt not_active IP Right Cessation
- 2003-04-16 AT AT03719766T patent/ATE389406T1/de not_active IP Right Cessation
- 2003-04-16 PE PE2003000390A patent/PE20040684A1/es not_active Application Discontinuation
- 2003-04-16 ES ES03719766T patent/ES2301791T3/es not_active Expired - Lifetime
- 2003-04-16 AR AR20030101340A patent/AR040405A1/es active IP Right Grant
- 2003-04-16 MX MXPA04010173A patent/MXPA04010173A/es active IP Right Grant
- 2003-04-16 CN CNB038137798A patent/CN100522166C/zh not_active Expired - Fee Related
- 2003-04-16 PL PL03373889A patent/PL373889A1/xx not_active Application Discontinuation
- 2003-04-16 SI SI200331201T patent/SI1499316T1/sl unknown
- 2003-04-16 EP EP03719766A patent/EP1499316B1/en not_active Expired - Lifetime
- 2003-04-16 DE DE60319813T patent/DE60319813T2/de not_active Expired - Lifetime
- 2003-04-16 PT PT03719766T patent/PT1499316E/pt unknown
- 2003-04-16 JP JP2003585719A patent/JP4384918B2/ja not_active Expired - Lifetime
- 2003-04-16 CA CA002481940A patent/CA2481940A1/en not_active Abandoned
- 2003-04-16 DK DK03719766T patent/DK1499316T3/da active
- 2003-04-16 WO PCT/US2003/011672 patent/WO2003088967A1/en not_active Ceased
- 2003-04-16 AU AU2003223627A patent/AU2003223627B2/en not_active Ceased
- 2003-04-16 KR KR1020047016508A patent/KR100827470B1/ko not_active Expired - Fee Related
- 2003-04-16 RU RU2004133764/04A patent/RU2323935C2/ru not_active IP Right Cessation
- 2003-04-17 TW TW092108912A patent/TW200306183A/zh unknown
-
2004
- 2004-10-04 ZA ZA200407984A patent/ZA200407984B/xx unknown
- 2004-10-14 IL IL164584A patent/IL164584A/en not_active IP Right Cessation
- 2004-10-15 EC EC2004005367A patent/ECSP045367A/es unknown
- 2004-11-17 NO NO20045002A patent/NO20045002L/no unknown
-
2008
- 2008-06-09 CY CY20081100604T patent/CY1110363T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4384918B2 (ja) | ヒスタミンｈ３アンタゴニストとして有用な（１−４−ピペリジニル）ベンズイミダゾール誘導体 | |
| US20040097483A1 (en) | Benzimidazole derivatives useful as histamine H3 antagonists | |
| JP4563800B2 (ja) | ヒスタミンｈ３アンタゴニストとしての１−（４−ピペリジニル）ベンズイミダゾロン | |
| JP4326468B2 (ja) | ヒスタミンｈ３アンタゴニストとして有用なインドール誘導体 | |
| JP4093859B2 (ja) | 抗アレルギー剤としてのピペリジン化合物 | |
| EP1313733A1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| EP0925299B1 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| JP2007533735A (ja) | ケモカイン受容体ｃｃｒ５のモジュレーターとしてのピペリジン誘導体 | |
| TW202527993A (zh) | 雙功能雄激素受體化合物 | |
| AU733034B2 (en) | Pyrazolopyridine compound and pharmaceutical use thereof | |
| HK1067981B (en) | (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080930 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20081001 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081222 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090129 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090129 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090915 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090928 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |